You just read:

Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease

News provided by

Ocugen, Inc.

Sep 25, 2017, 06:30 ET